Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma - Results of the Pomalidomide Mukseven (NCT02406222) Biomarker Trial
James Croft(Institute of Cancer Research), Martin Kaiser(Royal Marsden NHS Foundation Trust), Louise Flanagan(University of Leeds), Anjan Thakurta(University of Oxford), Mamta Garg(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Gordon Cook(University of Leeds), Maria Wang, Suzana S. Couto, Sidra Ellis(King's College - North Carolina), Kim A. Sharp(Institute of Cancer Research), Sarah Brown(University of Leeds), Charlotte Pawlyn(Royal Marsden NHS Foundation Trust), Katrina Walker(University of Leeds), William E. Pierceall(Bristol-Myers Squibb (Switzerland)), Andrew Hall(University of Leeds), Amy L. Sherborne(Institute of Cancer Research), Amy Price(Royal Free London NHS Foundation Trust), Kevin Boyd(Royal Marsden Hospital)
Cited by 4
Related Papers
Genome-wide association study identifies five susceptibility loci for glioma
|Nature Genetics|2009|797
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
|Blood|2020|657
Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial
|The Lancet|2010|640
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
|The Lancet|2010|571
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
|Journal of Clinical Oncology|2015|564